ABSTRACT
Fisher B, Dignam J, Mamounas HP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen-receptor negative tumors: eight year results from NSAPB B-13 and first report of findings from NSABP B-10 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil. Journal of Clinical Oncology 1996; 14:1982-1992. [In the NSABP B-13 trial, node-negative ER-negative patients were randomized to chemotherapy or to a no-treatment control group. Among the 235 patients treated with breast conserving sugery and radiotherapy, the 8-year rate of recurrence in the ipsilateral breast was 13.4% without chemotherapy and 2.6% with chemotherapy.]
Dalberg K, Johansson H, Johansson U, Rutqvist L, for the Stockholm Breast Cancer Study Group. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy for patients with early stage breast carcinoma treated with breast-conserving surgery. Cancer 1998; 82:2204-2211. [A similar result was seen in the Stockholm Breast Cancer Study Group among node-negative patients randomized to tamoxifen or to a placebo. Among the 432 patients treated with breast conserving surgery and radiotherapy, the 10-year rate of recurrence in the ipsilateral breast was 12% without tamoxifen and only 3% with tamoxifen.]
Related references (1)
(2)
Firm evidence was presented, based on large randomized clinical trials.
